Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-07

Clinical Trial Update: Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP 980 to trastuzumab in HER2-positive early breast cancer completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABP 980 (ABP 980)

Snippet

Sponsor: Amgen | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-08-07